Erik C. Emerson
President, Founder and Chief Executive Officer
Erik Emerson is a 15-year veteran of the pharmaceutical industry with an expansive background in sales and marketing. Most recently, Mr. Emerson worked as the Head of Commercial Development for XOMA (U.S.) LLC, where he led multiple business and commercial development deals and was responsible for building the commercial infrastructure for XOMA’s first and only commercial product in its 32-year history. Prior to this, Mr. Emerson advanced his commercial career with a move to Gilead Sciences, where he launched multiple initiatives for Gilead, including a unique program called LabSync®, which streamlined the ordering and tracking of laboratory work on behalf of physician offices and patients. Mr. Emerson began his career in field sales for King Pharmaceuticals before transitioning to sales training.
Jeff Feldstein, MD, FAAFP
Senior Vice President, Founder and Chief Medical Officer
Jeff Feldstein, MD, is a graduate of Rush Medical College and Fellow of the American Academy of Family Physicians. Most recently at XOMA, Dr. Feldstein led the cardiometabolic development of gevokizumab. He also had an integral role in structuring agreements to bring the perindopril franchise back to the United States through XOMA, and in subsequently working with Mr. Emerson to transition the franchise to Symplmed.
In 2000, Dr. Feldstein began his pharmaceutical medical career when he joined Sanofi-Organon LLC to launch ARIXTRA® (fondaparinux sodium) solution, the first synthetic factor Xa inhibitor. Later, he moved to Novartis specifically to take part in the Diovan® (valsartan tablets) pediatric trial. Upon leaving Novartis, Dr. Feldstein joined King Pharmaceuticals, serving as Director of Medical Affairs and later became a principal in the IMS Health strategic intelligence group.